A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Trial details

Who runs it

Exelixis

Trial code

NCT07428616

Record updated

28 October 2026

Original description

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.Read full original descriptionShow less

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Inclusion: Histologically confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma; Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and/or radiation) or have been deemed ineligible to receive these therapies. At least 1 prior course of meningioma-directed radiotherapy is required, if not contraindicated; Radiologically documented progression of any existing tumor (growth > 15% of the bidimensional enhancing tumor within the prior 6 months or appearance of new lesions (including intra and extracranial manifestations); For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion of therapy to initiation of treatment; Measurable disease by RANO meningioma criteria as determined by the investigator, obtained ≤ 14 days prior to initiation of treatment; Karnofsky performance status (KPS) ≥ 60%; Demonstrate adequate organ and marrow function within 14 days of treatment initiation.

Exclusion: Prior history of hypertensive encephalopathy at any time; Local therapy (surgery and/or radiation therapy) is indicated per investigator; Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks or 5 half-lives, whichever is shorter, before initiation of treatment. There is no limit on prior systemic therapies; Prior Surgery - completed wound healing must occur prior to initiation of treatment; ≥ 8 weeks for major surgery, ≥ 7 days for minor surgery, including stereotactic biopsies; The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:; Cardiovascular disorders, including uncontrolled hypertension,; Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation,; Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 milliliters [mL]) of red blood within 12 weeks before initiation of treatment or other history of significant bleeding (eg, intracranial hemorrhage/bleeding), or; Other clinically significant disorders; History of solid organ or allogeneic stem cell transplant; Note: Other protocol defined Inclusion/Exclusion criteria may apply; Extracranial lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta; Contraindication to magnetic resonance imaging (MRI); Requirement for hemodialysis or peritoneal dialysis.

ClinicalTrials.gov NCT07428616